New EU regulation on data privacy, the General Protection Data Regulation, shines a Light on the benefits of automation to safeguard patient data when monitoring safety signals and ensuring pharmacovigilance databases can track changes to personal data and create an audit trail to remain GDPR compliant. Read the blog

Whether companies like it or not, consumers are discussing their products in social media forums. Comments about adverse events exist on patient forums, and on more generic social forums such as Facebook and Twitter. While much of what is said is not relevant or verifiable, there are safety signals that companies should be paying attention to, and that go to the heart of pharmacovigilance and social media.

One of the key roles of pharmacovigilance departments is to understand the benefit-risk profile of a drug. But departments are often bogged down by manual tasks that can absorb time, which might be better spent on value-centric activities. Perhaps the most tedious pharmacovigilance activity is medical literature monitoring (MLM), and as we discussed in our last blog, manual, repetitive tasks are a primary cause of employee dissatisfaction.

During a recent webcast, ArisGlobal carried out an insightful survey, which found that visibility and reporting inefficiencies remain a headache.

Download this white paper to learn about. Pharmacovigilance with an ‘e’ – the “4pt-classification” of the state of evolution of national pharmacovigilance systems Modern technologies in pharmacovigilance system – the way forward for national PV systems Advanced pharmacovigilance technologies –the role ‘e- enablement’ technology plays in bridging the gaps in pharmacovigilance of regulatory authorities across the world

As a medical information software provider, it is necessary to recognize that there is some decent software out there in the life science’s space

Most sponsors and clinical research organisations manage clinical trials using ...